Enalare Therapeutics Inc. — Form D/A
Enalare Therapeutics Inc. of PRINCETON, NJ, a company, filed a Form D amendment with the SEC on 2020-12-21. The offering totals $10.0M. Industry: Pharmaceuticals.
Offering
- Filed: 2020-12-21
- Form: D/A
- Accession: 0001835701-20-000002
- Industry: Pharmaceuticals
- Exemptions: 06b
- Total offering: $10.0M
- Remaining: $10.0M
- Security types: debt
- Revenue range: Decline to Disclose
- SEC file number: 021-382994
Issuer
- Name: Enalare Therapeutics Inc.
- CIK: 0001835701
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2018
- Address: 161 HODGE ROAD, PRINCETON, NJ, 08540
- Phone: 609-325-7701
Officers, directors & promoters (9)
| Name | Role | Location |
|---|
| Gino Santini | Director | Cambridge, MA |
| Joseph Pergolizzi | Director | Summit, NJ |
| Joseph Pergolizzi | Executive Officer | Summit, NJ |
| Mark Coleman | Director | ROCKVILLE, MD |
| Robert Yedid | Director | Princeton, NJ |
| Daniel Motto | Executive Officer | Princeton, NJ |
| Joseph Petko | Director | Princeton, NJ |
| Herman Cukier | Director | Princeton, NJ |
| Herman Cukier | Executive Officer | Princeton, NJ |
Other filings by this issuer (3)
More